-transparent.png){kind=logo}
Controlled release carbidopa/levodopa (CSR-1) was compared to standard carbidopa/levodopa in a double-blind, crossover study of 20 Parkinson's disease patients. The most consistent finding in a variety of clinical measurements was the superiority of standard carbidopa/levodopa to CSR-1. Increased dosages of CSR-1 resulted in reduced Parkinson symptoms, suggesting that a more potent controlled-release formulation might prove to be more efficacious than CSR-1.
Related Publications
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
August 1988,
Archives of neurology,
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
March 2008,
Clinical toxicology (Philadelphia, Pa.),
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
January 1988,
Archives of neurology,
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
January 1998,
Neurology India,
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
November 2010,
International journal of clinical pharmacology and therapeutics,
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
June 1976,
Revista clinica espanola,
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
September 1999,
Neurology,
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
January 1990,
Journal of neural transmission. Parkinson's disease and dementia section,
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
January 1992,
Neurology,
J T Hutton, and
R L Dippel, and
J R Bianchine, and
H K Strahlendorf, and
P G Meyer
September 1986,
Neurology,
